Sign in to view content

Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials

Dilsher S. Dhoot, MD

Video
Published 2021

Related

Randomized Trial of PRP vs Intravitreal Ranibizumab Plus Deferred PRP for Proliferative Diabetic Retinopathy
Andrew N. Antoszyk, MD FASRS
Updates from the Field
2016
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more